Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Interventions and public health nutrition

Weight loss at your fingertips: personalized nutrition with fasting glucose and insulin using a novel statistical approach

Subjects

Abstract

Background/Objectives

Precision medicine is changing the way people are diagnosed and treated into a more personalized approach. Using a novel statistical approach, we demonstrate how two diets cause differential weight loss depending on pre-treatment fasting plasma glucose (FPG) and fasting insulin (FI) levels.

Subjects/Methods

One hundred and eighty-one overweight people with increased waist circumference were randomly assigned to receive an ad libitum New Nordic Diet (NND) high in dietary fiber and whole grain or an Average Danish (Western) Diet (ADD) for 26 weeks. All foods were provided free of charge. Body weight was measured throughout the study and blood was drawn before randomization from where FPG and FI were analyzed. Weight was described by linear mixed models including biomarker (FPG or FI) diet group interactions. Individualized predictions were estimated as contrasts of intercepts and slopes of pre-treatment biomarkers.

Results

Every mmol/L increase in baseline FPG predicted a between-diet difference of 3.00 (1.18;4.83, n = 181, P = 0.001) kg larger weight loss from choosing NND over ADD. For instance, a baseline FPG level of 4.7 mmol/L would lead to an average of 1.42 kg larger weight loss on NND vs. ADD (above 0.41 kg with 95% certainty), whereas the average effect size would be 8.33 kg (above 5.50 kg with 95% certainty) among subjects with FPG level of 7.0 mmol/L. Among individuals with FPG <5.6 mmol/L, each pmol/L lower baseline FI predicted a 0.039 (95% CI 0.017;0.061, n = 143, P < 0.001) kg larger weight loss from choosing NND over ADD.

Conclusions

Use of pre-treatment FPG and FI led to truly individualized predictions of treatment effect of introducing more fiber and whole grain in the diet on weight loss, ranging from almost no effect to losing >8 kg. These findings suggest that this novel statistical approach has great potential when re-evaluating data from existing randomized controlled trials.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2

References

  1. 1.

    Byrd JB. Personalized medicine and treatment approaches in hypertension: current perspectives. Integr Blood Press Control. 2016;9:59–67.

    CAS  Article  Google Scholar 

  2. 2.

    Walker LE, Mirza N, Yip VLM, Marson AG, Pirmohamed M. Personalized medicine approaches in epilepsy. J Intern Med. 2015. https://doi.org/10.1111/joim.12322.

  3. 3.

    Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE. Personalized approaches to active immunotherapy in cancer. Biochim Biophys Acta Rev Cancer. 2016. https://doi.org/10.1016/j.bbcan.2015.07.004.

  4. 4.

    MS O. Management of parkinson disease in 2017: personalized approaches for patient-specific needs. JAMA. 2017;318:791–2.

    Article  Google Scholar 

  5. 5.

    Cai T, Tian L, Wong PH, Wei LJ. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics. 2011. https://doi.org/10.1093/biostatistics/kxq060.

  6. 6.

    Chen S, Tian L, Cai T, Yu M. A general statistical framework for subgroup identification and comparative treatment scoring. Biometrics. 2017. https://doi.org/10.1111/biom.12676.

  7. 7.

    Ge J, Wang D, Fan L. Effect of personalized nutrition guidance on the birth rate of fetal macrosomia in Chinese population: a meta-analysis of nine randomized controlled trials. Cell Biochem Biophys. 2015. https://doi.org/10.1007/s12013-015-0512-0.

  8. 8.

    Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079–94.

    CAS  Article  Google Scholar 

  9. 9.

    Celis-Morales C, Livingstone KM, Marsaux CF, Macready AL, Fallaize R, O’Donovan CB et al. Effect of personalized nutrition on health-related behaviour change: evidence from the Food4Me European randomized controlled trial. Int J Epidemiol. 2017. https://doi.org/10.1093/ije/dyw186.

  10. 10.

    Hjorth MF, Ritz C, Blaak EE, Saris WH, Langin D, Poulsen SK, et al. Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials. Am J Clin Nutr. 2017;106:499–505.

    CAS  Article  Google Scholar 

  11. 11.

    Ruberg SJ, Shen L. Personalized medicine: four perspectives of tailored medicine. Stat Biopharm Res. 2015;7:214–29.

    Article  Google Scholar 

  12. 12.

    Fu H, Zhou J, Faries DE. Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies. Stat Med. 2016. https://doi.org/10.1002/sim.6920.

  13. 13.

    Poulsen SK, Due A, Jordy AB, Kiens B, Stark KD, Stender S, et al. Health effect of the New Nordic Diet in adults with increased waist circumference: a 6-mo randomized controlled trial. Am J Clin Nutr. 2014;99:35–45.

    CAS  Article  Google Scholar 

  14. 14.

    Pedersen AN, Fagt S, Groth MV, Christensen T, Biltoft-Jensen AP, Matthiessen J et al. Danskernes kostvaner 2003–2008. Hovedresultater (Dietary habits of Danes 2003–2008. Main results). DTU Fødevareinstituttet; 2010.

  15. 15.

    Fitzmaurice, GM, Laird, NM, Ware JH. Applied longitudinal analysis. 2nd ed. Wiley; 2011.

  16. 16.

    Ondra T, Dmitrienko A, Friede T, Graf A, Miller F, Stallard N, et al. Methods for identification and confirmation of targeted subgroups in clinical trials: a systematic review. J Biopharm Stat. 2016;26:99–119.

    Article  Google Scholar 

  17. 17.

    Zhao Y, Zeng D. Recent development on statistical methods for personalized medicine discovery. Front Med. 2013;7:102–10.

    Article  Google Scholar 

  18. 18.

    DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L. The personalized advantage index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS One. 2014. https://doi.org/10.1371/journal.pone.0083875

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Weisberg S. Applied linear regression. 3rd ed. New York: Wiley & Sons; 2005.

    Book  Google Scholar 

  20. 20.

    R Core Team. Computational many-particle physics. Berlin, Heidelberg: Springer; 2008. https://doi.org/10.1007/978-3-540-74686-7.

  21. 21.

    Renzella J, Townsend N, Jewell J, Breda J, Roberts N, Rayner MWK What national and subnational interventions and policies based on Mediterranean and Nordic diets are recommended or implemented in the WHO European Region, and is there evidence of effectiveness in reducing noncommunicable diseases? Copenhagen, 2018.

  22. 22.

    Hwang JJ, Jiang L, Hamza M, Sanchez Rangel E, Dai F, Belfort-DeAguiar R et al. Blunted rise in brain glucose levels during hyperglycemia in adults with obesity and T2DM. JCI Insight. 2017; 2. https://doi.org/10.1172/jci.insight.95913.

  23. 23.

    Slavin JL Dietary fiber and body weight. Nutrition. 2005. https://doi.org/10.1016/j.nut.2004.08.018.

  24. 24.

    Kang C, Janes H, Huang Y. Combining biomarkers to optimize patient treatment recommendations. Biometrics. 2014;70:695–707.

    Article  Google Scholar 

  25. 25.

    Janes H, Pepe MS, McShane LM, Sargent DJ, Heagerty PJ The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. J Natl Cancer Inst. 2015. https://doi.org/10.1093/jnci/djv157.

  26. 26.

    Varadhan R, Segal JB, Boyd CM, Wu AW, Weiss CO. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. J Clin Epidemiol. 2013;66:818–25.

    Article  Google Scholar 

  27. 27.

    Claggett B, Tian L, Castagno D, Wei LJ Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. Biostatistics. 2015. https://doi.org/10.1093/biostatistics/kxu037.

  28. 28.

    Minsker S, Zhao Y-Q, Cheng G. Active Clinical Trials for Personalized Medicine. J Am Stat Assoc. 2016;111:875–87.

    CAS  Article  Google Scholar 

  29. 29.

    Matsouaka RA, Li J, Cai T Evaluating marker-guided treatment selection strategies. Biometrics. 2014. https://doi.org/10.1111/biom.12179.

Download references

Acknowledgements

The Nordea Foundation Denmark funded the study and local food companies provided foods for the shop. Neither the funder nor the food sponsors had any influence on the study design, data collection, data analysis, data interpretation or the content and submission of this paper. We thank Sanne Kellebjerg Korndal that coordinated and executed the study as part of her PhD at the Department of Nutrition, Exercise and Sports, University of Copenhagen.

Funding

The overall study was supported by the Nordea Foundation (grant no. 02–2010–0389) and sponsors who provided foods to the shop.

Author information

Affiliations

Authors

Contributions

TML and AA designed and carried out the original study. CR and MFH designed the research plan for this stratified analysis; CR performed statistical analysis; CR and MFH wrote paper and have primary responsibility for final content; All authors have contributed to the discussion, reviewed the manuscript critically and approved the final manuscript.

Corresponding author

Correspondence to Mads F. Hjorth.

Ethics declarations

Conflict of interest

CR, AA and MFH are co-inventors on a pending provisional patent application for the use of biomarkers to predict responses to weight loss diets. AA is co-inventor of other related patents and patent applications that are owned by UCPH, in accordance with Danish law. AA is consultant or member of the advisory boards of Gelesis Inc., Groupe Ethique et Sante, France; Weight Watchers, United States; BioCare, Copenhagen; Zaluvida, Switzerland; Novo Nordisk, Denmark; Pfizer, New Jersey, USA; and Saniona, Denmark. MFH and AA are co-authors of the book Spis dig slank efter dit blodsukker (Eat according to your blood sugar and be slim), published by Politikens Forlag, Denmark, and of other books about personalized nutrition for weight loss. AA is co-owner and member of the board of the consultancy company Dentacom ApS, Denmark, and cofounder and co-owner of the UCPH spin-off Mobile Fitness A/S and Flax-Slim ApS. MFH and AA are co-founders and co-owners of the UCPH spin-off Personalized Weight Management Research Consortium ApS (http://Gluco-diet.dk). TML serves as an advisor for Sense diet program.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ritz, C., Astrup, A., Larsen, T.M. et al. Weight loss at your fingertips: personalized nutrition with fasting glucose and insulin using a novel statistical approach. Eur J Clin Nutr 73, 1529–1535 (2019). https://doi.org/10.1038/s41430-019-0423-z

Download citation

Further reading

Search

Quick links